Alexander Kabanov

Alexander Kabanov is a Distinguished Professor at the Eshelman School of Pharmacy, UNC-Chapel Hill, where he also directs the UNC Center for Nanotechnology in Drug Delivery, the Carolina Institute for Nanomedicine, and NCI’s T32 training program in Cancer Nanotechnology. He earned his Ph.D. and D.Sc. in Chemical Sciences from Moscow State University in 1987 and 1990, respectively.

 

Kabanov has made significant contributions to nanomedicine, pioneering the use of polymeric micelles, polyelectrolyte complexes, nanogels, andexosomes for delivering small drugs, nucleic acids, and proteins therapeutically. His work resulted in the first clinical trial involving a polymeric micelle drug. He is a highly cited researcher in Pharmacology and Toxicology, with over 340 scientific papers (>52,000 citations, Google h-index >117), 36 US patents, and co-founding several pharmaceutical companies.

 

He has mentored over 80 graduate students and postdocs, with a strong commitment to diversity. Kabanov also established symposium series in nanomedicine and drug delivery www.nanodds.org, chaired Gordon Research Conferences, and received numerous honors and awards, including the Lenin Komsomol Prize, NSF Career award, George Gamow award, and Controlled Release Society (CRS) Founders award.

 

He is an elected member or fellow of prestigious academies and organizations, including Academia Europaea, Russian Academy of Sciences, National Academy of Inventors, American Association for the Advancement of Science, American Institute for Medical and Biological Engineering, and CRS. He has served as the past President and current CEO of the Russian American Science Association, director-at-large for CRS (2019-2022), and chair of the CRS College of Fellows sub-committee (2022-2023).